Siglec receptors as new immune checkpoints in cancer.

Stanczak MA; Läubli H. Molecular aspects of medicine. 2023.

Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.

Berner F; Bomze D; Lichtensteiger C; Walter V; Niederer R; Hasan Ali O; Wyss N; Bauer J; Freudenmann LK; Marcu A; Wolfschmitt EM; Haen S; Gross T; Abdou MT; Diem S; Knöpfli S; Sinnberg T; Hofmeister K; Cheng HW; Toma M; Klümper N; Purde MT; Pop OT; Jochum AK; Pascolo S; Joerger M; Früh M; Jochum W; Rammensee HG; Läubli H; Hölzel M; Neefjes J; Walz J; Flatz L. Science Immunology. 2022.

Case report of elevation of high-sensitivity cardiac troponin T in the absence of cardiac involvement in immune checkpoint inhibitor-associated myositis.

Ruperti-Repilado FJ; van der Stouwe JG; Haaf P; Mueller C; Läubli H; Pfister O; Rothschild SI; Kuster GM. . 2022.

Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment.

Kirchhammer N; Trefny MP; Auf der Maur P; Läubli H; Zippelius A. Science Translational Medicine. 2022.

Editorial: Glycans: Masters of immunity, from cancers to inflammatory disease.

Beatson R; Läubli H; Pearce OMT; Reis CA. . 2022.

Editorial: Novel roles for tumor-associated neutrophils.

Mandruzzato S; Läubli H. . 2022.

Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.

Kostner L; Cerminara SE; Pamplona GSP; Maul JT; Dummer R; Ramelyte E; Mangana J; Wagner NB; Cozzio A; Kreiter S; Kogler A; Streit M; Wysocki A; Zippelius A; Läubli H; Navarini AA; Maul LV. Cancers. 2022.

Glycosaminoglycans in cancer therapy.

Wieboldt R; Läubli H. American journal of physiology. Cell physiology. 2022.

High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.

Vazquez-Lombardi R; Jung JS; Schlatter FS; Mei A; Mantuano NR; Bieberich F; Hong KL; Kucharczyk J; Kapetanovic E; Aznauryan E; Weber CR; Zippelius A; Läubli H; Reddy ST. Immunity. 2022.

Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma.

König D; Hench J; Frank S; Dima L; Bratic Hench I; Läubli H. . 2022.

Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.

Zeitlberger AM; Putora PM; Hofer S; Schucht P; Migliorini D; Hottinger AF; Roelcke U; Läubli H; Spina P; Bozinov O; Weller M; Neidert MC; Hundsberger T. Journal of neuro-oncology. 2022.

NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity.

Kirchhammer N; Trefny MP; Natoli M; Brücher D; Smith SN; Werner F; Koch V; Schreiner D; Bartoszek E; Buchi M; Schmid M; Breu D; Hartmann KP; Zaytseva P; Thommen DS; Läubli H; Böttcher JP; Stanczak MA; Kashyap AS; Plückthun A; Zippelius A. Science Translational Medicine. 2022.

Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.

Schumann K; Mauch C; Klespe KC; Loquai C; Nikfarjam U; Schlaak M; Akçetin L; Kölblinger P; Hoellwerth M; Meissner M; Mengi G; Braun AD; Mengoni M; Dummer R; Mangana J; Sindrilaru MA; Radmann D; Hafner C; Freund J; Rappersberger K; Weihsengruber F; Meiss F; Reinhardt L; Meier F; Rainer B; Richtig E; Ressler JM; Höller C; Eigentler T; Amaral T; Peitsch WK; Hillen U; Harth W; Ziller F; Schatton K; Gambichler T; Susok L; Maul LV; Läubli H; Debus D; Weishaupt C; Börger S; Sievers K; Haferkamp S; Zenderowski V; Nguyen VA; Wanner M; Gutzmer R; Terheyden P; Kähler K; Emmert S; Thiem A; Sachse M; Gercken-Riedel S; Kaune KM; Thoms KM; Heinzerling L; Heppt MV; Tratzmiller S; Hoetzenecker W; Öllinger A; Steiner A; Peinhaupt T; Podda M; Schmid S; Wollina U; Biedermann T; Posch C. Journal of the European Academy of Dermatology and Venereology : JEADV. 2022.

Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer.

Wang J; Manni M; Bärenwaldt A; Wieboldt R; Kirchhammer N; Ivanek R; Stanczak M; Zippelius A; König D; Rodrigues Manutano N; Läubli H. Frontiers in cell and developmental biology. 2022.

speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing.

Castellanos-Rueda R; Di Roberto RB; Bieberich F; Schlatter FS; Palianina D; Nguyen OTP; Kapetanovic E; Läubli H; Hierlemann A; Khanna N; Reddy ST. Nature Communications. 2022.

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.

Stanczak MA; Rodrigues Mantuano N; Kirchhammer N; Sanin DE; Jacob F; Coelho R; Everest-Dass AV; Wang J; Trefny MP; Monaco G; Bärenwaldt A; Gray MA; Petrone A; Kashyap AS; Glatz K; Kasenda B; Normington K; Broderick J; Peng L; Pearce OMT; Pearce EL; Bertozzi CR; Zippelius A; Läubli H. Science Translational Medicine. 2022.

Targeting immunoliposomes to EGFR-positive glioblastoma.

Kasenda B; König D; Manni M; Ritschard R; Duthaler U; Bartoszek E; Bärenwaldt A; Deuster S; Hutter G; Cordier D; Mariani L; Hench J; Frank S; Krähenbühl S; Zippelius A; Rochlitz C; Mamot C; Wicki A; Läubli H. ESMO Open. 2022.

Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.

Läubli H; Nalle SC; Maslyar D. . 2022.

A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration.

Werner F; Wagner C; Simon M; Glatz K; Mertz KD; Läubli H; Griss J; Wagner SN. Frontiers in immunology. 2021.

Cross-reactivity and functionality of approved human immune checkpoint blockers in dogs

Pantelyushin S.; Ranninger E.; Guerrera D.; Hutter G.; Maake C.; Markkanen E.; Bettschart-Wolfensberger R.; Bley C.R.; Laubli H.; Vom Berg J.. Cancers. 2021.

Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM).

Hofer S; Keller K; Imbach L; Roelcke U; Hutter G; Hundsberger T; Hertler C; Le Rhun E; Vasella F; Cordier D; Neidert M; Hottinger A; Migliorini D; Pflugshaupt T; Eggenberger N; Baumert B; Läubli H; Gramatzki D; Reinert M; Pesce G; Schucht P; Frank I; Lehnick D; Weiss T; Wirsching HG; Wolpert F; Roth P; Weller M. Swiss medical weekly. 2021.

Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma.

Werner F; Wagner C; Simon M; Glatz K; Mertz KD; Läubli H; Richtig E; Griss J; Wagner SN. Diagnostics (Basel, Switzerland). 2021.

Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors

Konig D.; Laubli H.. PHARMACOLOGY. 2021.

Multidisciplinary tumor boards as videoconferences - a new challenge in the COVID-19 era.

Gross MW; Läubli H; Cordier D. Annals of oncology : official journal of the European Society for Medical Oncology. 2021.

Targeting glyco-immune checkpoints for cancer therapy

Manni M.; Laubli H.. EXPERT OPINION ON BIOLOGICAL THERAPY. 2021.

Tools to study and target the Siglec–sialic acid axis in cancer

Laubli H.; Kawanishi K.; George Vazhappilly C.; Matar R.; Merheb M.; Sarwar Siddiqui S.. The FEBS journal. 2021.

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults

Roth P.; Hottinger A.F.; Hundsberger T.; Laubli H.; Schucht P.; Reinert M.; Mamot C.; Roelcke U.; Pesce G.; Hofer S.; Weller M.. Swiss medical weekly. 2020.

A sweet approach to heat up cancer response to immunotherapy

Pearce O.M.T.; Laubli H.. Cancer Discovery. 2020.

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.

Trüb M; Uhlenbrock F; Claus C; Herzig P; Thelen M; Karanikas V; Bacac M; Amann M; Albrecht R; Ferrara-Koller C; Thommen D; Rothschield S; Savic Prince S; Mertz KD; Cathomas G; Rosenberg R; Heinzelmann-Schwarz V; Wiese M; Lardinois D; Umana P; Klein C; Laubli H; Kashyap AS; Zippelius A. Journal for ImmunoTherapy of Cancer. 2020.

Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation.

Rodrigues Mantuano N; Stanczak MA; Oliveira IA; Kirchhammer N; Filardy AA; Monaco G; Santos RC; Fonseca AC; Fontes M; Bastos CS Jr; Dias WB; Zippelius A; Todeschini AR; Läubli H. Cancer immunology research. 2020.

PD-1(+) natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade.

Trefny MP; Kaiser M; Stanczak MA; Herzig P; Savic S; Wiese M; Lardinois D; Läubli H; Uhlenbrock F; Zippelius A. Cancer immunology, immunotherapy : CII. 2020.

Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153-e154.

Trinh B; Donath MY; Läubli H. . 2020.

Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.

Läubli H; Varki A. . 2020.

Targeted glycan degradation potentiates the anticancer immune response in vivo.

Gray MA; Stanczak MA; Mantuano NR; Xiao H; Pijnenborg JFA; Malaker SA; Miller CL; Weidenbacher PA; Tanzo JT; Ahn G; Woods EC; Läubli H; Bertozzi CR. Nature Chemical Biology. 2020.

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy.

Rodrigues Mantuano N; Natoli M; Zippelius A; Läubli H. Journal for ImmunoTherapy of Cancer. 2020.

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P. Journal of Pathology. 2020.

Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis.

Läubli H; Borsig L. Frontiers in Immunology. 2019.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

Berner F; Bomze D; Diem S; Ali OH; Fässler M; Ring S; Niederer R; Ackermann CJ; Baumgaertner P; Pikor N; Cruz CG; van de Veen W; Akdis M; Nikolaev S; Läubli H; Zippelius A; Hartmann F; Cheng HW; Hönger G; Recher M; Goldman J; Cozzio A; Früh M; Neefjes J; Driessen C; Ludewig B; Hegazy AN; Jochum W; Speiser DE; Flatz L. JAMA oncology. 2019.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.

Trefny MP; Rothschild SI; Uhlenbrock F; Rieder D; Kasenda B; Stanczak MA; Berner F; Kashyap AS; Kaiser M; Herzig P; Poechtrager S; Thommen DS; Geier F; Savic S; Jermann P; Alborelli I; Schaub S; Stenner F; Früh M; Trajanoski Z; Flatz L; Mertz KD; Zippelius A; Läubli H. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019.

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.

Griss J; Bauer W; Wagner C; Simon M; Chen M; Grabmeier-Pfistershammer K; Maurer-Granofszky M; Roka F; Penz T; Bock C; Zhang G; Herlyn M; Glatz K; Läubli H; Mertz KD; Petzelbauer P; Wiesner T; Hartl M; Pickl WF; Somasundaram R; Steinberger P; Wagner SN. Nature Communications. 2019.

GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses.

Kashyap AS; Fernandez-Rodriguez L; Zhao Y; Monaco G; Trefny MP; Yoshida N; Martin K; Sharma A; Olieric N; Shah P; Stanczak M; Kirchhammer N; Park SM; Wieckowski S; Laubli H; Zagani R; Kasenda B; Steinmetz MO; Reinecker HC; Zippelius A. Cell Reports. 2019.

Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Läubli H; Dirnhofer S; Zippelius A. Virchows Archiv. 2019.

Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.

Trinh B; Sanchez GO; Herzig P; Läubli H. Journal for ImmunoTherapy of Cancer. 2019.

Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Cheng WC; Tsui YC; Ragusa S; Koelzer VH; Mina M; Franco F; Läubli H; Tschumi B; Speiser D; Romero P; Zippelius A; Petrova TV; Mertz K; Ciriello G; Ho PC. . 2019.

Siglec-9 Regulates an Effector Memory CD8(+) T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.

Haas Q; Boligan KF; Jandus C; Schneider C; Simillion C; Stanczak MA; Haubitz M; Seyed Jafari SM; Zippelius A; Baerlocher GM; Läubli H; Hunger RE; Romero P; Simon HU; von Gunten S. Cancer immunology research. 2019.

Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab.

Trinh B; Donath MY; Läubli H. Diabetes care. 2019.

Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX).

Liewen H; Markuly N; Läubli H; Liu Y; Matter MS; Liewen N; Renner C; Zippelius A; Stenner F. Targeted Oncology. 2019.

The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.

Bärenwaldt A; Läubli H. Expert opinion on therapeutic targets. 2019.

Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation.

Ortega Sanchez G; Stenner F; Dirnhofer S; Passweg J; Gerull S; Halter JP; Zippelius A; Läubli H. Swiss medical weekly. 2019.

Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Cheng WC; Tsui YC; Ragusa S; Koelzer VH; Mina M; Franco F; Läubli H; Tschumi B; Speiser D; Romero P; Zippelius A; Petrova TV; Mertz K; Ciriello G; Ho PC. Nature immunology. 2019.

Cancer Immunotherapy.

Pearce OMT; Läubli H. GLYCOBIOLOGY. 2018.

Cell adhesion during tumorigenesis and metastasis

Borsig L.; Laubli H.. . 2018.

Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.

Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI. Swiss medical weekly. 2018.

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.

Läubli H; Balmelli C; Kaufmann L; Stanczak M; Syedbasha M; Vogt D; Hertig A; Müller B; Gautschi O; Stenner F; Zippelius A; Egli A; Rothschild SI. Journal for ImmunoTherapy of Cancer. 2018.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H. Journal of Clinical Investigation. 2018.

Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.

Adams OJ; Stanczak MA; von Gunten S; Läubli H. GLYCOBIOLOGY. 2018.

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.

Läubli H; Müller P; D'Amico L; Buchi M; Kashyap AS; Zippelius A. Cancer immunology, immunotherapy : CII. 2018.

The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.

Läubli H; Koelzer VH; Matter MS; Herzig P; Dolder Schlienger B; Wiese MN; Lardinois D; Mertz KD; Zippelius A. Oncoimmunology. 2018.

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.

Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H. Journal for ImmunoTherapy of Cancer. 2018.

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.

Läubli H; Hench J; Stanczak M; Heijnen I; Papachristofilou A; Frank S; Zippelius A; Stenner-Liewen F. Journal for ImmunoTherapy of Cancer. 2017.

Antimetastatic Properties of Low Molecular Weight Heparin.

Läubli H; Varki A; Borsig L. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.

Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder.

Läubli H; Tzankov A; Juskevicius D; Degen L; Rochlitz C; Stenner-Liewen F. Leukemia & lymphoma. 2016.

Sialic acids in cancer biology and immunity.

Pearce OM; Läubli H. GLYCOBIOLOGY. 2016.

The immune system and cancer evasion strategies: therapeutic concepts.

Muenst S; Läubli H; Soysal SD; Zippelius A; Tzankov A; Hoeller S. Journal of Internal Medicine. 2016.

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.

Läubli H; Balmelli C; Bossard M; Pfister O; Glatz K; Zippelius A. Journal for ImmunoTherapy of Cancer. 2015.

A red meat-derived glycan promotes inflammation and cancer progression.

Samraj AN; Pearce OM; Läubli H; Crittenden AN; Bergfeld AK; Banda K; Gregg CJ; Bingman AE; Secrest P; Diaz SL; Varki NM; Varki A. Proceedings of the National Academy of Sciences of the United States of America. 2015.

Reply to Mackenzie: A comparison of Neu5Gc and α-gal xenoantigens.

Pearce OM; Samraj AN; Läubli H; Varki NM; Varki A. Proceedings of the National Academy of Sciences of the United States of America. 2015.

Siglec receptors impact mammalian lifespan by modulating oxidative stress.

Schwarz F; Pearce OM; Wang X; Samraj AN; Läubli H; Garcia JO; Lin H; Fu X; Garcia-Bingman A; Secrest P; Romanoski CE; Heyser C; Glass CK; Hazen SL; Varki N; Varki A; Gagneux P. Elife. 2015.

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.

Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A. Proceedings of the National Academy of Sciences of the United States of America. 2014.

Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

Pearce OM; Läubli H; Bui J; Varki A. Oncoimmunology. 2014.

Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies.

Pearce OM; Läubli H; Verhagen A; Secrest P; Zhang J; Varki NM; Crocker PR; Bui JD; Varki A. Proceedings of the National Academy of Sciences of the United States of America. 2014.

Involvement of a non-human sialic Acid in human cancer.

Samraj AN; Läubli H; Varki N; Varki A. Frontiers in oncology. 2014.

Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A. The Journal of biological chemistry. 2014.

Selectins as mediators of lung metastasis.

Läubli H; Borsig L. Cancer microenvironment : official journal of the International Cancer Microenvironment Society. 2010.

Selectins promote tumor metastasis.

Läubli H; Borsig L. SEMINARS IN CANCER BIOLOGY. 2010.

Heparins attenuate cancer metastasis: are selectins the link?

Laubli H; Borsig L. CANCER INVESTIGATION. 2009.

Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes.

Läubli H; Spanaus KS; Borsig L. Blood. 2009.

L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest.

Läubli H; Stevenson JL; Varki A; Varki NM; Borsig L. Cancer research. 2006.